Equillium, Inc. (EQ)
NASDAQ: EQ · Real-Time Price · USD
0.880
-0.004 (-0.49%)
At close: Feb 21, 2025, 4:00 PM
0.870
-0.010 (-1.14%)
After-hours: Feb 21, 2025, 5:31 PM EST
Equillium Revenue
Equillium had revenue of $12.16M in the quarter ending September 30, 2024, with 37.10% growth. This brings the company's revenue in the last twelve months to $45.91M, up 7.70% year-over-year. In the year 2023, Equillium had annual revenue of $36.08M with 128.97% growth.
Revenue (ttm)
$45.91M
Revenue Growth
+7.70%
P/S Ratio
0.68
Revenue / Employee
$1,043,500
Employees
44
Market Cap
31.18M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
EQ News
- 16 days ago - Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis - Business Wire
- 3 months ago - Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates - Business Wire
- 3 months ago - Equillium to Present at the Stifel Healthcare Conference - Business Wire
- 3 months ago - Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer - Business Wire
- 4 months ago - Equillium Maintains Rights to Itolizumab Following Ono Partnership - Business Wire
- 4 months ago - Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer - Business Wire
- 5 months ago - Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit - Business Wire
- 6 months ago - Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire